Home » Stocks » KDNY

Chinook Therapeutics, Inc. (KDNY)

Stock Price: $15.15 USD -0.63 (-3.99%)
Updated May 12, 2021 4:00 PM EDT - Market closed
Market Cap 675.58M
Revenue (ttm) 827,000
Net Income (ttm) -81.62M
Shares Out 13.17M
EPS (ttm) -6.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $15.15
Previous Close $15.78
Change ($) -0.63
Change (%) -3.99%
Day's Open 15.68
Day's Range 15.13 - 16.07
Day's Volume 123,831
52-Week Range 10.50 - 21.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SEATTLE, May 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

3 hours ago - GlobeNewsWire

SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

1 week ago - GlobeNewsWire

SEATTLE, April 15, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

3 weeks ago - GlobeNewsWire

SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

1 month ago - GlobeNewsWire

SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

1 month ago - GlobeNewsWire

Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2022

1 month ago - GlobeNewsWire

Van Herk Investments to Form and Invest in Sairopa, a New Company Focused on Research and Development of B-Select Monoclonal Antibody Platform Programs

1 month ago - GlobeNewsWire

VANCOUVER, British Columbia and SEATTLE, April 01, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercializa...

1 month ago - GlobeNewsWire

Chinook (KDNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 month ago - Zacks Investment Research

VANCOUVER, British Columbia and SEATTLE, March 30, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercializa...

1 month ago - GlobeNewsWire

Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to Begin Enrollment in the First Half of 2021

1 month ago - GlobeNewsWire

VANCOUVER, British Columbia and SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercializa...

2 months ago - GlobeNewsWire

Chinook (KDNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

VANCOUVER, British Columbia and SEATTLE, March 01, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY) and Evotec SE today announced a strategic collaboration focused on the discovery and...

2 months ago - GlobeNewsWire

Chinook Therapeutics Inc (NASDAQ: KDNY) and Evotec SE (OTCMKTS: EVTCY) have collaborated for the discovery and development of precision medicine therapies for patients with chronic kidney diseases (CKD)...

Other stocks mentioned: EVTCY
2 months ago - Benzinga

Head of Renal Discovery and Translational Medicine, Andrew King, D.V.M., Ph.D., to Present on Atrasentan and Participate in Expert Panel Discussion on Executing Precision Medicine in Clinical Trials

2 months ago - GlobeNewsWire

VANCOUVER, British Columbia and SEATTLE, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercializat...

2 months ago - GlobeNewsWire

The FDA has granted Rare Pediatric Disease status to Chinook Therapeutics Inc's (NASDAQ: KDNY) CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A for primary hyperoxalu...

3 months ago - Benzinga

CHK-336 On Track for Phase 1 Clinical Trial Initiation in the Second Half of 2021

3 months ago - GlobeNewsWire

VANCOUVER, British Columbia and SEATTLE, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercializat...

4 months ago - GlobeNewsWire

VANCOUVER, British Columbia and SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and...

5 months ago - GlobeNewsWire

Aduro Biotech (KDNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Other stocks mentioned: ADRO
5 months ago - Zacks Investment Research

Aduro Biotech (KDNY) delivered earnings and revenue surprises of -291.30% and 37.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: ADRO
6 months ago - Zacks Investment Research

Aduro Biotech (KDNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: ADRO
6 months ago - Zacks Investment Research

Aduro Biotech (KDNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Other stocks mentioned: ADRO
6 months ago - Zacks Investment Research

Does Aduro Biotech (KDNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Other stocks mentioned: ADRO
6 months ago - Zacks Investment Research

Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY”

Other stocks mentioned: ADRO
7 months ago - GlobeNewsWire

One-for-Five Reverse Stock Split to be Effective October 2, 2020

Other stocks mentioned: ADRO
7 months ago - GlobeNewsWire

Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, raised an additional $106 million just before its planned merger with Aduro Biotech.

Other stocks mentioned: ADRO
8 months ago - GeekWire

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -10.53% and 76.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: ADRO
9 months ago - Zacks Investment Research

BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation Inducin...

Other stocks mentioned: ADRO
9 months ago - GlobeNewsWire

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: ADRO
9 months ago - Zacks Investment Research

BERKELEY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interfero...

Other stocks mentioned: ADRO
10 months ago - GlobeNewsWire

Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, has agreed to merge with Berkeley, Calif.

Other stocks mentioned: ADRO
11 months ago - GeekWire

BERKELEY, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interfero...

Other stocks mentioned: ADRO
11 months ago - GlobeNewsWire

– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy

Other stocks mentioned: ADRO
11 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Aduro Biotech.

Other stocks mentioned: ADRO
11 months ago - Zacks Investment Research

Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Other stocks mentioned: ADRO
11 months ago - Zacks Investment Research

Is (ADRO) Outperforming Other Medical Stocks This Year?

Other stocks mentioned: ADRO
11 months ago - Zacks Investment Research

Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Other stocks mentioned: ADRO
1 year ago - Zacks Investment Research

Aduro Biotech (ADRO) delivered earnings and revenue surprises of 18.18% and 58.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: ADRO
1 year ago - Zacks Investment Research

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: ADRO
1 year ago - Zacks Investment Research

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock?

Other stocks mentioned: ADRO
1 year ago - Zacks Investment Research

Aduro Biotech (ADRO) closed the most recent trading day at $2.54, moving +1.2% from the previous trading session.

Other stocks mentioned: ADRO
1 year ago - Zacks Investment Research

Is (ADRO) Outperforming Other Medical Stocks This Year?

Other stocks mentioned: ADRO
1 year ago - Zacks Investment Research

Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.

Other stocks mentioned: ADRO
1 year ago - Zacks Investment Research

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -14.29% and -26.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: ADRO
1 year ago - Zacks Investment Research

Aduro Biotech (ADRO) closed the most recent trading day at $3.33, moving -0.6% from the previous trading session.

Other stocks mentioned: ADRO
1 year ago - Zacks Investment Research

After a painful stretch, small-cap U.S. stocks should rebound on a few tailwinds.

Other stocks mentioned: ADRO, RAD, SMED, TNAV, VXRT
1 year ago - Zacks Investment Research

Is (ADRO) Outperforming Other Medical Stocks This Year?

Other stocks mentioned: ADRO
1 year ago - Zacks Investment Research

About KDNY

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatme... [Read more...]

Industry
Biotechnology
CEO
Stephen Isaacs
Employees
105
Stock Exchange
NASDAQ
Ticker Symbol
KDNY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for KDNY stock is "Strong Buy." The 12-month stock price forecast is 31.71, which is an increase of 109.31% from the latest price.

Price Target
$31.71
(109.31% upside)
Analyst Consensus: Strong Buy